Home » Newsletters » BioWorld

BioWorld

Feb. 19, 1992

View Archived Issues

AMYLIN SPEEDS UP TRIAL PLANS

NVX VACCINE DEAL WITH DANES

APPLIED BIOSYSTEMS SETTLES PATENT CLAIM

HEMACARE REGISTERS SHARES

NOVEN FILES TO SELL 2.5M SHARES

TRIALS START ON BLOOD SUBSTITUTE

EPITOPE, SMITHKLINE TO END COLLABORATION

BARD SEEKS TRIALS OF BIOMATRIX GEL

INCYTE PATENT FOR SEPSIS TREATMENT

DRUG BLOCKS HIV ENTRY INTO CELLS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...